Literature DB >> 31867072

Radioimmunotherapy (RIT) in Brain Tumors.

Ali Gholamrezanezhad1, Hossein Shooli2, Narges Jokar2, Reza Nemati3, Majid Assadi2.   

Abstract

Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor-related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care. © Korean Society of Nuclear Medicine 2019.

Entities:  

Keywords:  Brain tumors; Monoclonal antibody (mAb); Radioimmunotherapy (RIT)

Year:  2019        PMID： 31867072      PMCID： PMC6898703          DOI： 10.1007/s13139-019-00618-6

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  69 in total

1.  Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling.

Authors:  Bin Hu; Mohan S Nandhu; Hosung Sim; Paula A Agudelo-Garcia; Joshua C Saldivar; Claire E Dolan; Maria E Mora; Gerard J Nuovo; Susan E Cole; Mariano S Viapiano
Journal:  Cancer Res       Date:  2012-06-04       Impact factor: 12.701

2.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

3.  Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.

Authors:  P Riva; G Franceschi; M Frattarelli; S Lazzari; N Riva; G Giuliani; M Casi; G Sarti; G Guiducci; G Giorgetti; R Gentile; M Santimaria; E Jermann; H R Maeke
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.

Authors:  Stefan Kneifel; Dominik Cordier; Stephan Good; Mihai C S Ionescu; Anthony Ghaffari; Silvia Hofer; Martin Kretzschmar; Markus Tolnay; Christos Apostolidis; Beatrice Waser; Marlene Arnold; Jan Mueller-Brand; Helmut R Maecke; Jean Claude Reubi; Adrian Merlo
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

5.  Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas.

Authors:  Mohan S Nandhu; Bin Hu; Susan E Cole; Anat Erdreich-Epstein; Diego J Rodriguez-Gil; Mariano S Viapiano
Journal:  Cancer Res       Date:  2014-08-19       Impact factor: 12.701

6.  Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose.

Authors:  K Hopkins; C Chandler; J Eatough; T Moss; J T Kemshead
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

7.  Tenascin expression in human glioma cell lines and normal tissues.

Authors:  J B Ventimiglia; C J Wikstrand; L E Ostrowski; M A Bourdon; V A Lightner; D D Bigner
Journal:  J Neuroimmunol       Date:  1992-01       Impact factor: 3.478

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Authors:  E Franceschi; G Cavallo; S Lonardi; E Magrini; A Tosoni; D Grosso; L Scopece; V Blatt; B Urbini; A Pession; G Tallini; L Crinò; A A Brandes
Journal:  Br J Cancer       Date:  2007-03-13       Impact factor: 7.640

10.  Tenascin-C signaling through induction of 14-3-3 tau.

Authors:  Doris Martin; Marianne Brown-Luedi; Ruth Chiquet-Ehrismann
Journal:  J Cell Biol       Date:  2003-01-13       Impact factor: 10.539
View more
  3 in total

1.  Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device.

Authors:  Sheila S McThenia; Neeta Pandit-Taskar; Milan Grkovski; Maria A Donzelli; Safiatu Diagana; Jeffrey P Greenfield; Mark M Souweidane; Kim Kramer
Journal:  J Neurooncol       Date:  2022-04-11       Impact factor: 4.130

2.  Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies.

Authors:  Agata Pietrzak; Andrzej Marszałek; Jolanta Kunikowska; Tomasz Piotrowski; Adrianna Medak; Katarzyna Pietrasz; Julia Wojtowicz; Witold Cholewiński
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

Review 3.  Current Immunotherapeutic Approaches for Malignant Gliomas.

Authors:  Myung-Hoon Han; Choong Hyun Kim
Journal:  Brain Tumor Res Treat       Date:  2022-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.